Funded Biotechnology Startups in Atlanta
Across the 10 most recent biotechnology rounds listed for Atlanta, Vero Biotech’s $100M round (2021-12-21) is a clear outlier: the next-largest disclosed a…
Across the 10 most recent biotechnology rounds listed for Atlanta, Vero Biotech’s $100M round (2021-12-21) is a clear outlier: the next-largest disclosed amount is $96M from Antios Therapeutics (2021-04-12), while most other disclosed rounds sit far lower (e.g., $27M in 2022-06-22 for Florence Healthcare; $7M in 2023-09-05 for Lucid Scientific; $5M in 2025-10-22 for Andson Biotech). The disclosed amounts are also concentrated in a mid-range of dates: three entries run from 2023-10-19 to 2023-11-15 (BioCircuit Technologies, $2M; Hypercell Technologies, $1M; and Lucid Scientific’s $7M appears just earlier on 2023-09-05), and the overall window spans 2021-04-12 through 2025-10-22.
Stage labels are split between later rounds and incomplete disclosure: “Series Unknown” appears for 2 companies (Andson Biotech, 2025-10-22; Moonlight Therapeutics, 2025-10-16), and “undisclosed” appears for 2 entries (Moonlight Therapeutics; Clearwave on 2021-10-26). Beyond the Atlanta location field, the list is entirely biotechnology, so the main analytical variation is in disclosure depth and round size rather than geography or sector mix.
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed round is largest, and how does it compare to the rest of the Atlanta biotechnology entries shown?
Vero Biotech’s $100M (2021-12-21) is the largest disclosed amount, narrowly above Antios Therapeutics’ $96M (2021-04-12). The next-largest disclosed after those sits well below $50M, with Florence Healthcare at $27M (2022-06-22) and Lucid Scientific at $7M (2023-09-05).
Do the round dates cluster into a narrow window, or are they spread out across multiple periods?
There is a noticeable late-2023 cluster: BioCircuit Technologies ($2M, 2023-10-19) and Hypercell Technologies ($1M, 2023-11-15) bookend that period, with Lucid Scientific ($7M, 2023-09-05) immediately preceding. Outside that, rounds extend across multiple years, spanning 2021-04-12 (Antios Therapeutics) through 2025-10-22 (Andson Biotech).
How much of the list has incomplete deal disclosure (Series Unknown vs “undisclosed amounts”)?
Two entries use “Series Unknown” (Andson Biotech, Series Unknown, 2025-10-22; Moonlight Therapeutics, Series Unknown, 2025-10-16). “Undisclosed” amounts appear for two companies as well: Moonlight Therapeutics (2025-10-16) and Clearwave (Private Equity, 2021-10-26).
What stage mix dominates among the labeled rounds in this slice of Atlanta biotech?
Later-stage labels are prominent: Series C (Florence Healthcare, $27M on 2022-06-22) and Series E (Vero Biotech, $100M on 2021-12-21) sit alongside Series B (Antios Therapeutics, $96M on 2021-04-12) and Series A (Lucid Scientific, $7M on 2023-09-05). Earlier or ambiguous labels appear in smaller disclosed sizes, like Venture–Series Unknown for TendoNova ($450K on 2022-08-22).
Are there outliers in disclosed size besides the top-end rounds?
Yes. TendoNova’s $450K (2022-08-22) is the smallest disclosed amount in the rows shown, sitting far below other mid-tier rounds like Hypercell Technologies at $1M (2023-11-15) and BioCircuit Technologies at $2M (2023-10-19). This makes the disclosed-size distribution wide, from $450K up to $100M.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.